Charles E. Lyon

Dr. Charles Lyon provides strategic insight to investors and life sciences companies, both VC-backed and publicly-traded, to help them maximize the value of their investments in intellectual property by condensing complex data into actionable insights. Through hundreds of due diligence and intellectual property analysis projects, Charles has helped clients to understand, evaluate, and respond to IP issues that arise in the context of business transactions or during the research and development of new products and technologies. His insights have helped clients to identify “hot” areas in the life sciences landscape which have driven their strategic investment decisions – notably in the areas of immuno-oncology, gene therapy, gene editing, and cell therapy. He also routinely provides advice and opinions regarding freedom-to-operate and intellectual property landscape issues to assist with R&D decisions and in the context of pre-litigation disputes including Hatch-Waxman and Biosimilar litigation.

Charles has served investor clients including Bain Capital, Deerfield Management, 5AM Ventures, Third Rock Ventures, Venrock, Perceptive Advisors, and Broadview Ventures and life sciences companies including Takeda, Gilead, Biogen, GEMoaB, Editas Medicine, and Akouos.